Virtu KCG Holdings’s Avadel Pharmaceuticals AVDL Stock Holding History

Virtu KCG Holdings’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$259K	Buy	+23,461	New	+$236K	0.01%	1857
2016 Q4	–	Sell	-19,366	Closed	-$240K	–	3379
2016 Q3	$240K	Buy	+19,366	New	+$253K	0.01%	2169
2016 Q2	–	Sell	-20,992	Closed	-$232K	–	2935
2016 Q1	$232K	Buy	20,992 +5,110	+32%	+$50.8K	0.01%	1944
2015 Q4	$194K	Buy	+15,882	New	+$248K	﹤0.01%	2737
2014 Q1	–	Sell	-14,478	Closed	-$116K	–	3509
2013 Q4	$116K	Buy	+14,478	New	+$102K	﹤0.01%	3399

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Virtu KCG Holdings's AVDL Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Avadel Pharmaceuticals (AVDL) in Q2 2017: 23,461 shares worth $259K. The stake represents 0.01% of the portfolio and ranks #1857 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in AVDL as recently as Q3 2016.

Virtu KCG Holdings first reported a position in AVDL in Q4 2013 and has held it in 5 quarters since. 78 funds tracked by Wall St. Rank hold AVDL as of Q2 2017.

Virtu KCG Holdings held 23,461 shares of Avadel Pharmaceuticals worth $259K as of Q2 2017.
Avadel Pharmaceuticals was a new Virtu KCG Holdings position in Q2 2017.
Avadel Pharmaceuticals made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1857 holding.
Virtu KCG Holdings first reported a position in Avadel Pharmaceuticals in Q4 2013 and has held it in 5 quarters since.
78 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.